1. Home
  2. SCHL vs ABUS Comparison

SCHL vs ABUS Comparison

Compare SCHL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$40.25

Market Cap

842.4M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCHL
ABUS
Founded
1920
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.4M
848.8M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
SCHL
ABUS
Price
$40.25
$4.56
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$40.00
$5.00
AVG Volume (30 Days)
262.4K
1.2M
Earning Date
03-19-2026
05-14-2026
Dividend Yield
1.99%
N/A
EPS Growth
N/A
55.26
EPS
1.87
0.87
Revenue
$1,487,100,000.00
$14,083,000.00
Revenue This Year
$1.88
N/A
Revenue Next Year
$4.05
$239.71
P/E Ratio
$21.91
$5.28
Revenue Growth
N/A
128.21
52 Week Low
$16.81
$3.04
52 Week High
$43.39
$5.10

Technical Indicators

Market Signals
Indicator
SCHL
ABUS
Relative Strength Index (RSI) 52.51 57.10
Support Level $37.84 $4.16
Resistance Level $43.39 $4.60
Average True Range (ATR) 1.23 0.18
MACD 0.03 0.04
Stochastic Oscillator 68.36 67.81

Price Performance

Historical Comparison
SCHL
ABUS

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: